Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS(R) (raltegravir) 600 mg in the European Union

KENILWORTH, N.J.--(Healthcare Sales & Marketing Network)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted... Biopharmaceuticals, Regulatory Merck, ISENTRESS, raltegravir, HIV/AIDS
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news